CMN Weekly (27 January 2023) - Your Weekly CRISPR Medicine News
Some of the best links we picked up around the internet
By: Gorm Palmgren - Jan. 27, 2023
TALEN gene-edited allogeneic CAR T cells show feasibility and preliminary efficacy for treating multiple myeloma in interim results from the phase 1 UNIVERSAL trial. Of forty-three patients treated with the ALLO-715 therapeutic product, 56% showed an objective response and a median response duration of 8.3 months. While adverse events grade ≥ 3 occurred in 88% of patients, these were mainly haematological conditions (12-70% of patients). Other grade ≥ 3 adverse events occurred as infections in 23% of patients, cytokine release syndrome in 2% and neurotoxicity in 0%. TALEN gene editing was used to abolish the expression of TRAC and CD52, thereby reducing graft-versus-host disease and increasing CAR T cell survival, respectively.
Chinese researchers have developed a fluorescent aptasensor system for detecting nasopharyngeal carcinoma-derived exosomes. The system is based on combining magnetic nanoparticles, terminal deoxynucleotidyl transferase (TdT), CRISPR/Cas12a, and a nucleic acid aptamer. The TdT can form an ultra-long polynucleotide tail which can bind with multiple crRNA, generating a signal amplification effect. The method exhibited excellent sensitivity and specificity, with a linear range between 500 to 5 × 104 particles mL−1 and a detection limit of 100 particles mL−1.
Advances in RT-LAMP for COVID-19 testing and diagnosis. This review by American researchers discusses the role of RT-LAMP within the context of other technologies like RT-qPCR and rapid antigen tests. The focus is on progress in sample preparation strategies to enable simplified workflow for RT-LAMP directly from clinical specimens, new challenges with primer and assay design for the evolving pandemic, prominent detection modalities including colourimetric and CRISPR-mediated methods, and translational research and commercial development of RT-LAMP for clinical applications.